Here, we report the engineering and testing of BiMAb and bifunctional TNFL fusion proteins targeting various well-established breast cancer-associated TAAs, including EGFR, HER2, CEA, EpCAM, and the tumor stroma antigen FAP. The gene discussed is EPCAM; the disease is neoplasm.